For citations:
Cherenova S.G., Rubanenko O.A., Rubanenko A.O., Gritsenko T.A., Lomaia E.G., Turkina А.G., Davydkin I.L. Changes in laboratory indicators of endothelial dysfunction and lipid spectrum in patients with chronic myeloid leukemia treated with the second-generation tyrosine kinase inhibitor bosutinib. Bulletin of the Medical Institute "REAVIZ" (REHABILITATION, DOCTOR AND HEALTH). 2025;15(6):34-45. (In Russ.) https://doi.org/10.20340/vmi-rvz.2025.6.CLIN.4
JATS XML

















